Last reviewed · How we verify
SR1375
At a glance
| Generic name | SR1375 |
|---|---|
| Sponsor | Shanghai SIMR Biotechnology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of SR1375 in Adult Patients With CAP (PHASE2)
- A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375 (PHASE1)
- The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SR1375 CI brief — competitive landscape report
- SR1375 updates RSS · CI watch RSS
- Shanghai SIMR Biotechnology Co., Ltd. portfolio CI